Funding
← Back to your selection

RA Capital Management

Activity from announced rounds

Activity in this selectionOct 24, 2026 · Enterprise software · Jan 1, 2026

RA Capital Management founds, funds and scales companies in healthcare and planetary health, combining scientific research with capital from seed through public-market financings.

Its TechAtlas research platform informs investment decisions through detailed scientific and market analysis. Raven, its healthcare incubator, works on originating and co-creating companies, giving researchers a route from a scientific idea to a funded business.

Blackbird provides a clinical development accelerator alongside the investment platform. These capabilities are relevant for founders who need to design a development programme and reach clinical milestones, as well as finance laboratory or commercial work.

Sources
Rounds participated in
6
Confirmed lead rounds
—
6 roles undisclosed
New companies
6
First participation on record · 0 follow-on
Funding in participating rounds
$685.5M
6 disclosed · full round size, not this investor’s share

By stage

Series A2
Series B2
Growth1
Undisclosed1

By primary sector

Biotech5
Healthtech1

By country

United States6

Rounds

6 in this selection
Ollin Biosciences

Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD

$330MSeries B
Role not disclosed
NorthLinks Bio

Develops broad-spectrum antiviral prophylactic therapies for respiratory infections

$34MUndisclosed
Role not disclosed
Contraline

Develops hormonal and non-hormonal male contraceptives for men and couples globally

$92.5MSeries B
Role not disclosed
Secretome Therapeutics

Clinical-stage company developing neonatal cardiac progenitor cell therapies for Duchenne-associated cardiomyopathy

$30MSeries A
Role not disclosed
NexCure

Provides CAR-T and other advanced treatment delivery in community outpatient settings

$19MSeries A
Role not disclosed